Rigel Q2 2026: VEPPANU License Kickstarts a PROTAC Pivot, While 2026 Revenue Outlook Holds Steady

Q2 highlights: revenue mix, profitability, and near-term catalysts

Rigel reported total quarterly revenue of $78.7 million, comprised of $67.0 million from net product sales and $11.7 million from collaboration revenues. Net income reached $17.3 million, underscoring a profitable quarter on a GAAP basis even as the company eyes a broader, more diversified revenue stream beyond legacy hematology and oncology products.

The release does not publish earnings per share (EPS) or an explicit EPS consensus in the materials, leaving investors to infer per-share impact once those numbers are disclosed in upcoming filings or quarterly releases. Still, the absence of an EPS figure today means any “earnings surprise” assessment will hinge on forthcoming data rather than the Q2 print alone. The headline takeaway is less about a one-quarter number and more about a strategic turn toward PROTAC-powered opportunities.

VEPPANU license: a new commercial horizon, a PROTAC milestone

Rigel entered an exclusive, global licensing agreement with Arvinas, Inc. and Pfizer Inc. to develop, manufacture, and commercialize VEPPANU (vepdegestrant). VEPPANU is notable as the first FDA-approved PROTAC for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. The deal became effective on June 11, 2026, and management expects VEPPANU to be commercially available in the U.S. later this month.

In a world where PROTACs are increasingly viewed as a strategic modality rather than a niche, VEPPANU represents a potential revenue-driver cue for Rigel’s portfolio. The collaboration could shift some revenue mix toward licensing and milestone-based payments, potentially affecting future EPS cadence and the leverage of the company’s pipeline beyond TAVALISSE, GAVRETO, and REZLIDHIA. The market will be watching how quickly VEPPANU translates into payer coverage, pricing, and actual sales once launched.

R&D momentum: R289 and the development path ahead

The company reiterates progress on the R289 development program, with a Phase 1b study in lower-risk myelodysplastic syndrome (MDS) on track to complete enrollment in the dose-expansion portion and select a recommended Phase 2 dose in the second half of 2026. This signals ongoing optionality in Rigel’s pipeline and the potential to extend the company’s addressable market if data meet or exceed expectations.

Combined with VEPPANU’s entry, Rigel is steering its narrative toward a more diversified growth profile—one that blends legacy product revenue with collaborative and potential future product licensing milestones. It remains to be seen how this mix will affect long-run profitability and how it interacts with EPS and consensus estimates in future quarters.

Outlook and strategic implications for the sector

Management issued a 2026 revenue forecast of approximately $285 to $295 million, broken down as roughly $255 to $265 million in net product sales (excluding VEPPANU) and about $30 million in contract revenues from collaborations. The forecast does not bake VEPPANU revenue into the near-term numbers, suggesting the VEPPANU opportunity is treated as a future growth vector rather than an immediate cash contributor.

From a sector perspective, Rigel’s deal with Arvinas and Pfizer underscores a broader industry appetite for external collaborations around PROTACs and other advanced modalities. If VEPPANU achieves its launch milestones and demonstrates real-world effectiveness, peers with PROTAC pipelines or late-stage assets may find a blueprint for monetizing partnerships that balance near-term product sales with longer-term, milestone-driven revenue streams.

What to watch next

Investors should monitor the 4:30 p.m. ET conference call for management's take on VEPPANU’s market access timeline, early launch performance, and any updates to the revenue guidance contingent on VEPPANU milestones. In the near term, the key questions hinge on per-share outcomes (EPS) once the company reports next quarter, whether the VEPPANU license begins contributing meaningfully to earnings, and how the R289 data readout shapes the risk-reward profile of Rigel’s pipeline versus sector peers exploring PROTAC and other targeted modalities.

Closing thought: a pivot worth watching

Rigel is not reinventing the wheel so much as rebranding its future around a PROTAC-enabled growth story. The Q2 print is punctuated by solid profitability and a strategic licensing arrangement that could recalibrate both the revenue mix and the earnings narrative in the years ahead. For the sector, Rigel’s VEPPANU deal is a bellwether of how big pharma and biotech partnerships can accelerate the commercialization of innovative modalities, even as the day-to-day earnings rhythm continues to be shaped by product sales and the cadence of clinical readouts.